The document summarizes a study that tested a novel antifungal drug (Drug A) in a murine model of invasive pulmonary aspergillosis. Mice were infected with Aspergillus fumigatus and then received various doses of Drug A or a positive control, Posaconazole. The mice were divided into groups for assessing fungal burden or survival. Higher doses of Drug A and Posaconazole reduced fungal counts in the lungs, showing the drug's antifungal activity. However, Drug A unexpectedly increased mouse mortality compared to controls, suggesting it may be toxic. The results point to an experimental error requiring the study to be repeated.